NASDAQ:FENC
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc.'s revenue fell 6.1% in fiscal 2025 to $44.6M while operating margin fell to −14.1%. The diluted share count rose 4.7%.Summary generated from Fennec Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$44.6M
Revenue growth−6.1%
Revenue, 5-yr CAGR+204.7%
Gross marginn/a
Operating margin−14.1%
Net margin−21.8%
ROICn/a
Return on equity−65.8%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+4.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 2 | 21 | 48 | 45 |
| Operating income | −17 | −23 | −13 | 3 | −6 |
| Net income | −17 | −24 | −16 | −0 | −10 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Oct 1, 2026 - 4Insider transaction report
Oct 1, 2026 - 8-KOther events
Sep 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of a shareholder vote
Jun 10, 2026 - 8-KOther events
May 22, 2026 - 8-KDirector or officer change
May 18, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026